Patent: 7,446,190
✉ Email this page to a colleague
Summary for Patent: 7,446,190
| Title: | Nucleic acids encoding chimeric T cell receptors |
| Abstract: | Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 ΞΆ-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation. |
| Inventor(s): | Michel Sadelain, Renier Brentjens, John Maher |
| Assignee: | Memorial Sloan Kettering Cancer Center |
| Application Number: | US10/448,256 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,446,190
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Juno Therapeutics, Inc. A Bristol Myer-squibb Company | BREYANZI | lisocabtagene maraleucel | Injection | 125714 | February 05, 2021 | 7,446,190 | 2023-05-28 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
